Autopsy report · NCT04284488

Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

“Company Strategy”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 4 years 8 months before it stopped.
• 40 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Ascentage Pharma Group Inc.

Sponsor type

Industry

Conditions

Advanced Solid Tumor

Interventions

APG-1387 for Injection; Toripalimab

Participants

40

Sites

3

Countries

China

Trials that died the same way

• A Phase I, the Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002
  “Business strategy” (85% match in meaning)
• Evaluate the Efficacy and Safety of Amnion Membrane Disc Allograft vs Standard of Care in Participants With Dry Eye Disease
  “Change in company strategy.” (83% match in meaning)
• A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome
  “Company's strategic decision” (80% match in meaning)
• Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
  “Strategic corporate decision” (76% match in meaning)
• Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
  “Company development strategy change” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.